Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression

ST. Aherne, SF. Madden, DJ. Hughes, B. Pardini, A. Naccarati, M. Levy, P. Vodicka, P. Neary, P. Dowling, M. Clynes,

. 2015 ; 15 (-) : 329. [pub] 20150430

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16010252

BACKGROUND: Screening for the early detection of colorectal cancer is important to improve patient survival. The aim of this study was to investigate the potential of circulating cell-free miRNAs as biomarkers of CRC, and their efficiency at delineating patients with polyps and benign adenomas from normal and cancer patient groups. METHODS: The expression of 667 miRNAs was assessed in a discovery set of 48 plasma samples comprising normal, polyp, adenoma, and early and advanced cancer samples. Three miRNAs (miR-34a, miR-150, and miR-923) were further examined in a validation cohort of 97 subjects divided into the same five groups, and in an independent public dataset of 40 CRC samples and paired normal tissues. RESULTS: High levels of circulating miR-34a and low miR-150 levels distinguished groups of patients with polyps from those with advanced cancer (AUC = 0.904), and low circulating miR-150 levels separated patients with adenomas from those with advanced cancer (AUC = 0.875). In addition, the altered expression of miR-34a and miR-150 in an independent public dataset of forty CRC samples and paired normal tissues was confirmed. CONCLUSION: We identified two circulating miRNAs capable of distinguishing patient groups with different diseases of the colon from each other, and patients with advanced cancer from benign disease groups.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010252
003      
CZ-PrNML
005      
20160412122745.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-015-1327-5 $2 doi
024    7_
$a 10.1186/s12885-015-1327-5 $2 doi
035    __
$a (PubMed)25924769
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Aherne, Sinéad T $u Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. sinead.aherne@dcu.ie. $7 gn_A_00002365
245    10
$a Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression / $c ST. Aherne, SF. Madden, DJ. Hughes, B. Pardini, A. Naccarati, M. Levy, P. Vodicka, P. Neary, P. Dowling, M. Clynes,
520    9_
$a BACKGROUND: Screening for the early detection of colorectal cancer is important to improve patient survival. The aim of this study was to investigate the potential of circulating cell-free miRNAs as biomarkers of CRC, and their efficiency at delineating patients with polyps and benign adenomas from normal and cancer patient groups. METHODS: The expression of 667 miRNAs was assessed in a discovery set of 48 plasma samples comprising normal, polyp, adenoma, and early and advanced cancer samples. Three miRNAs (miR-34a, miR-150, and miR-923) were further examined in a validation cohort of 97 subjects divided into the same five groups, and in an independent public dataset of 40 CRC samples and paired normal tissues. RESULTS: High levels of circulating miR-34a and low miR-150 levels distinguished groups of patients with polyps from those with advanced cancer (AUC = 0.904), and low circulating miR-150 levels separated patients with adenomas from those with advanced cancer (AUC = 0.875). In addition, the altered expression of miR-34a and miR-150 in an independent public dataset of forty CRC samples and paired normal tissues was confirmed. CONCLUSION: We identified two circulating miRNAs capable of distinguishing patient groups with different diseases of the colon from each other, and patients with advanced cancer from benign disease groups.
650    _2
$a adenom $x krev $x patologie $7 D000236
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x biosyntéza $x genetika $7 D014408
650    _2
$a polypy tlustého střeva $x krev $x patologie $7 D003111
650    _2
$a kolorektální nádory $x krev $x genetika $x patologie $7 D015179
650    12
$a diferenciální diagnóza $7 D003937
650    _2
$a progrese nemoci $7 D018450
650    _2
$a časná detekce nádoru $7 D055088
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x krev $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Madden, Stephen F $u Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. Stephen.madden@dcu.ie.
700    1_
$a Hughes, David J $u Department of Physiology and Medical Physics and Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin 2, Ireland. davidhughes@rcsi.ie.
700    1_
$a Pardini, Barbara $u Human Genetics Foundation, Turin, Italy. barbara.pardini@hugef.org.
700    1_
$a Naccarati, Alessio $u Human Genetics Foundation, Turin, Italy. alessio.naccarati@hugef.org. Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic. alessio.naccarati@hugef.org.
700    1_
$a Levy, Miroslav $u 1st Medical Faculty of Charles University and Thomayer Hospital, Prague, Czech Republic. miroslav.levy@ftn.cz.
700    1_
$a Vodicka, Pavel $u Institute of Experimental Medicine, Academy of Sciences of the Czech Republic, Prague, Czech Republic. pvodicka@biomed.cas.cz.
700    1_
$a Neary, Paul $u Department of Colorectal Surgery, AMNCH Hospital, Dublin 24, Ireland. paul.neary@amnch.ie.
700    1_
$a Dowling, Paul $u Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. paul.dowling@nuim.ie. Department of Biology, Maynooth University, Maynooth Co., Maynooth, Co. Kildare, Ireland. paul.dowling@nuim.ie.
700    1_
$a Clynes, Martin $u Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. Martin.Clynes@dcu.ie.
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 15, č. - (2015), s. 329
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25924769 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160412122828 $b ABA008
999    __
$a ok $b bmc $g 1113681 $s 934620
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 15 $c - $d 329 $e 20150430 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
LZP    __
$a Pubmed-20160408

Find record

Citation metrics

Archiving options